CoolCryo photo

CoolCryoQuick and Powerful Cryoablation

Cardiac Cryoablation System

CoolCryo is a cardiac cryoablation technology that uses liquid nitrogen as the cooling medium. Liquid nitrogen is widely available, commonly used, and one of the most cost-effective cooling agents, which significantly reduces the cost of the procedure and increases its accessibility. One of the key advantages of CoolCryo is its heated, formable tip, which enables fast ablation and thus shortens the duration of the procedure.

The Problem

Atrial fibrillation (AFib) is the most common heart rhythm disorder that causes the upper chambers of the heart to beat irregularly and often rapidly.

Uncontrolled atrial fibrillation can lead to serious complications, including stroke, heart failure, and chronic fatigue—significantly reducing quality of life. Common issues include:

  • stroke risk up to 5× higher
  • breathlessness, dizziness, palpitations
  • other unusual symptoms that often go unnoticed
PacePress schema

When Catheter Ablation Works — and When It May Not

  • Catheter ablation is an effective treatment for atrial fibrillation (AFib) and other arrhythmias. It targets small areas of heart tissue causing abnormal signals, helping restore normal rhythm and reduce symptoms.
  • Its success varies with disease stage. In advanced or long-standing AFib, results may not last. Some patients need extra treatments such as surgical ablation.
PacePress schema

Challenges in Surgical Ablation

Surgeons point to the low usability of current systems and prolonged application time. Key limitations include insufficient freezing power, difficulty ablating thick tissues, inability to perform ablation on a beating heart, high equipment costs, and limited access to coolant. During mitral valve surgery, 46% of surgeons report no barriers, but some cite added cross-clamp time (23%) or high patient risk (13%) as reasons preventing wider use of existing systems.

Source: Mehaffey, J. Hunter, et al. „Barriers to atrial fibrillation ablation during mitral valve surgery.” The Journal of thoracic and cardiovascular surgery 165.2 (2023): 650-658.

Challenges in surgical ablation

The Solution

CoolCryo for surgical ablation

At least four times faster procedure for surgical ablation

Possibility of ablating very thick tissues, potentially also the ventricle

Possibility of ablating on a beating heart

Access through sternotomy or minimally invasive methods

CoolCryo

Patented design and functionalities

Easily accessible, non-toxic, and inexpensive cooling medium

FDA 510k application submitted in June 2025

Recruited 14 out of 16 patients in the clinical study for EU CE MDR

Freezing curves CoolCryo vs competition

Potential application of CoolCryo in ventricular tachycardia

A recent use case highlights a promising new application of CoolCryo in the treatment of ventricular tachycardia (VT). While pharmacotherapy is typically the first-line treatment for electrical storm, recurrent ventricular arrhythmias may require thoracic sympathectomy or surgical ablation, particularly when catheter-based techniques are ineffective. In patients who cannot tolerate heart arrest, beating-heart ablation is preferred; however, conventional cryoablation systems using argon or nitrous oxide often lack adequate freezing power. CoolCryo, leveraging liquid nitrogen’s superior freezing capacity, addresses these limitations by enabling effective ablation regardless of heart wall thickness or blood flow.Click here for more details

Patented design and functionalities

Our CoolCryo technology is protected by a wide portfolio of international patents, highlighting our commitment to innovation. Patents granted in major areas such as Poland, US, Canada, China, Japan, South Korea, India, EPO, and WPO.

CoolCryo is protected by a comprehensive and wide-ranging intellectual property protection strategy. This broad protection ensures uniqueness, reliability, and competitive advantage of our technology worldwide.

CoolCryo patents
More about our innovations

We Care About Your Privacy

Medinice S.A. uses cookies to improve and customize users experience on our website. By selecting 'Accept', you consent to the use of all cookies that gather and use information about your interactions with our site to provide personalized content and enhance your digital experience. Please read our Privacy Policy for more information.

Contact

Address

Hankiewicza 2

02-103 Warszawa

Poland

Follow us

NIP: 6631868308

REGON: 260637552

KRS: 0000443282

EU logos
EU logos
EU logos